CFDE Data Portal | Search CRIM1-DT

	Label	Description
	CRIM1-DT Gene (Entity type)	ENSG00000260025 - CRIM1 divergent transcript
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE147662 3 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

CRIM1-DT

ENSG00000260025 - CRIM1 divergent transcript

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

A Gene Set from LINCS

GSE147662 3 V 1 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE238213 dopamine 1 v 0 human dn

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

A Gene Set from LINCS

GSE238213 dopamine 2 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.